CLINICAL_TRIALS
trial_result
· 2019-05-16
Clinical Trial Update: Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis [Phase 2]
Summary
An open-label extension study for NEOD001 in AL amyloidosis was terminated; results were posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Prothena Biosciences Ltd. | Conditions: AL Amyloidosis | Phase 2 | Status: TERMINATED | Results posted: 2019-05-16